Vaccinex, Inc. (NASDAQ:VCNX) Sees Large Decline in Short Interest

Vaccinex, Inc. (NASDAQ:VCNX) saw a significant decline in short interest in August. As of August 31st, there was short interest totalling 57,900 shares, a decline of 37.8% from the August 15th total of 93,100 shares. Approximately 7.4% of the shares of the stock are short sold. Based on an average trading volume of 76,000 shares, the short-interest ratio is currently 0.8 days.

Vaccinex Stock Performance

Shares of VCNX opened at $5.61 on Friday. Vaccinex has a 12-month low of $4.21 and a 12-month high of $51.98. The company has a market cap of $8.89 million, a PE ratio of -0.07 and a beta of 0.99. The stock has a 50-day moving average price of $5.86 and a 200-day moving average price of $6.36.

Vaccinex (NASDAQ:VCNX) last announced its earnings results on Wednesday, August 14th. The company reported ($3.10) earnings per share (EPS) for the quarter. The business had revenue of $0.23 million for the quarter.

Insider Activity at Vaccinex

In other news, Director Albert Friedberg purchased 200,000 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The shares were purchased at an average price of $6.15 per share, with a total value of $1,230,000.00. Following the completion of the acquisition, the director now owns 762,415 shares in the company, valued at approximately $4,688,852.25. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Over the last 90 days, insiders bought 203,753 shares of company stock valued at $1,247,255. Corporate insiders own 51.50% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Vaccinex stock. AIGH Capital Management LLC grew its position in shares of Vaccinex, Inc. (NASDAQ:VCNX) by 86.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 108,958 shares of the company’s stock after purchasing an additional 50,593 shares during the period. AIGH Capital Management LLC owned about 6.90% of Vaccinex worth $707,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 50.11% of the company’s stock.

Vaccinex Company Profile

Vaccinex, Inc, a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D.